Comparing the Performance of Serum Creatinine and Cystatin C-based GFR Estimations in Predicting Directly Measured GFR in Patients With or Without Nephrotic Syndrome

Launched by MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH · Jan 21, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how well two different tests—serum creatinine and cystatin C—can predict kidney function in patients with nephrotic syndrome, a condition that affects how the kidneys filter waste. The trial involves patients who are already participating in other studies testing new treatments for nephrotic syndrome. Researchers will take blood samples from these patients to measure cystatin C levels and compare the results to direct measurements of kidney function.

To be eligible, participants must be enrolled in one of the related clinical trials (PEPTIDE, MONET, or ORION) and must agree to allow their blood samples to be stored for future testing. This study is not yet recruiting participants, but when it begins, individuals who meet these criteria can expect to contribute to important research that may help improve kidney function assessments in patients with nephrotic syndrome.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects enrolled in the PEPTIDE, MONET, and ORION clinical trials (NCT04095156, NCT04893096, and NCT05050214 respectively).
• • Provision of written informed consent consent to store samples at the Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Ranica (BG) in the certified biobank UNI EN ISO 9001:2015; certification n° 6121 - Centro di Risorse Biologiche Mario Negri - Biobanca Malattie Rare e Malattie Renali (CRB).
• Exclusion Criteria:
• • Subjects not enrolled in the above mentioned trials.